Eledon Pharmaceuticals, Inc. (ELDN): Price and Financial Metrics


Eledon Pharmaceuticals, Inc. (ELDN): $3.57

-0.08 (-2.19%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ELDN to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

ELDN Stock Price Chart Interactive Chart >

Price chart for ELDN

ELDN Price/Volume Stats

Current price $3.57 52-week high $9.90
Prev. close $3.65 52-week low $2.27
Day low $3.40 Volume 36,300
Day high $3.75 Avg. volume 59,453
50-day MA $3.23 Dividend yield N/A
200-day MA $4.65 Market Cap 49.11M

Eledon Pharmaceuticals, Inc. (ELDN) Company Bio


Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for people undergoing organ or cellular transplantation, and for people with autoimmune and neurodegenerative disease.


ELDN Latest News Stream


Event/Time News Detail
Loading, please wait...

ELDN Latest Social Stream


Loading social stream, please wait...

View Full ELDN Social Stream

Latest ELDN News From Around the Web

Below are the latest news stories about Eledon Pharmaceuticals Inc that investors may wish to consider to help them evaluate ELDN as an investment opportunity.

Eledon Pharmaceuticals Provides Corporate Update and 2022 Outlook

Completed enrollment of all four cohorts in ongoing Phase 2a study with tegoprubart (AT-1501) in Amyotrophic Lateral Sclerosis (ALS) Announces USAN Approval of Generic Name “tegoprubart” for lead asset AT-1501 Catalyst-rich period ahead with four clinical trial readouts anticipated in 2022 Well capitalized with sufficient cash to fund operations into 2024 IRVINE, Calif., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical stage bio

Yahoo | February 14, 2022

Eledon Pharmaceuticals to Participate in 11th Annual SVB Leerink Global Healthcare Conference

IRVINE, Calif., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of innovative and impactful treatments for organ and cell transplantation, autoimmune conditions, and neurodegenerative disease, today announced that David-Alexandre C. Gros, M.D., Chief Executive Officer, will participate in a fireside chat at the 11th Annual SVB Leerink Virtual Global Healthcare Confere

Yahoo | February 8, 2022

2 “Strong Buy” Penny Stocks That Could See Outsized Gains

For investors seeking the strongest possible returns, there has always been a clear path. It involves risk, but the rewards are real. We’re talking, of course, about the outsized gains available in penny stocks, the low-priced equities that can slide under the radar. Historically, these are shares that sold for less than an old English shilling – just pennies. Later, they were defined as stocks selling for less than a one dollar per share; today, they’re the shares priced at less than $5. No mat

Yahoo | January 13, 2022

Eledon Pharmaceuticals to Participate in January 2022 Investor Conferences

IRVINE, Calif., Dec. 27, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of innovative and impactful treatments for organ and cell transplantation, autoimmune conditions, and neurodegenerative disease, today announced that members of management will be participating in two upcoming virtual investor conferences: Event:LifeSci Partners Corporate Access Event (January 5-7, 2022)F

Yahoo | December 27, 2021

A number of insiders bought Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) stock last year, which is great news for shareholders

Usually, when one insider buys stock, it might not be a monumental event. But when multiple insiders are buying like...

Yahoo | December 24, 2021

Read More 'ELDN' Stories Here

ELDN Price Returns

1-mo 17.05%
3-mo -7.03%
6-mo -29.31%
1-year -62.50%
3-year N/A
5-year N/A
YTD -19.05%
2021 -71.36%
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7684 seconds.